- Vir Biotechnology (NASDAQ:VIR) perks up 3% premarket on light volume on the heels of encouraging data early-stage data on VIR-2482, an intramuscularly administered influenza A-neutralizing monoclonal antibody in development for the prevention of influenza A. The results will be presented at the IDWeek conference.
- VIR-2482 showed broad neutralizing ability (against all major strains from the last 100 years), high-level effector function, extended half-life and tolerability. The prolonged half-life could potentially support once-per-season dosing.
- A Phase 1/2 study is ongoing.
- https://seekingalpha.com/news/3624192-vir-biotech-up-3-on-encouraging-data-on-influenza-candidate
Wednesday, October 21, 2020
Vir Biotech up 3% on encouraging data on influenza A candidate
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.